泽璟制药(688266.SH)：注射用ZG006与依托泊苷及顺铂联用获得药物临床试验批准通知书

Core Viewpoint - Zai Lab (688266.SH) has received approval from the National Medical Products Administration for a clinical trial of its injectable ZG006 in combination with Etoposide and Cisplatin for advanced neuroendocrine carcinoma [1] Group 1 - The clinical trial approval indicates progress in Zai Lab's oncology pipeline, particularly for treatments targeting advanced neuroendocrine cancers [1] - ZG006 is positioned to potentially enhance treatment options in a challenging cancer segment, reflecting the company's commitment to oncology research [1]